Sign up
Pharma Capital

Analyst sees 'clear rationale' for ImmuPharma to move forward with Lupuzor

The Life Sciences Division's Dr Navid Malik offers up his thoughts and outlook on ImmuPharma PLC (LON:IMM) and its flagship drug Lupuzor - a treatment for the autoimmune disease Lupus.

Dr Malik says despite not meeting its primary end point in a recent phase III trial, the response rate overall compares well to a number of other pivotal studies and has an excellent safety profile.

Worldwide, there are 5mln people with Lupus, 1.5mln of them in the US, Europe and Japan.

 

View full IMM profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.